HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 11, November 2018 – The Asian Cancer - War on liver cancer       » 2018 Nobel Prize in Physiology or Medicine winners       » Women more prone to selected chemotherapy side effects       » Tibetan fungus could help fight liver cancer       » Standards for TCM decoction to be applied globally       » RMB200 million donation to build Tsinghua University Biomedical Sciences Building      
NEWS CRUNCH
Anti-CD25 monoclonal antibody (90Y-daclizumab) a favorable target towards systemic radio-immunotherapy in Hodgkin's Lymphoma

6th October 2015 – The IL-2 receptor α subunit, CD25 is commonly expressed in T-regulatory (Treg) cells and a small subset of Reed-Sternberg cells in Hodgkin's Lymphoma (HL). Normal resting cells do not express CD25. An article published by Janik et. al 2015 (PNAS) stated that the predominant motivation to engage anti-CD25 in HL radioimmunotherapy is the expression of CD25 on T cells rosetting around Reed-Sternberg cells. Thereby, non-CD25 expressing tumor cells can also be killed during the crossfire of the battlefield when a high radiation dose is delivered.

90Y has a high β-energy emission, with a mean path length of 5mm and a maximum of 11mm. In Janik's study, the two clinical studies of relapsed-HL consecutive patients who were studied between April 2003 and October 2007 (n=30); between November 2009 and June 2014 (n=16) used daclizumab, a humanized anti-Tac, i.e. anti-CD25. The recruited patients received 90Y-daclizumba every 6-10 week and with a maximum cap of seven doses.

The clinical study presented encouraging results of 90Y-daclizumab radioimmunotherapy in relapsed HL patients: 30.4% complete responses and 19.6% partial responses. The patients' follow-up responses showed minor toxicity - thrombocytopenia and granulocytopenia.

However, six of the 30 patients in the first study presented myelodysplastic syndrome (MDS). Though MDS is a concern in oncology studies, the study is unable to draw supportive conclusions on whether 90Y-daclizumab may trigger MDS among HL patients with different medical histories and whom have received different combinations of onco-therapies.

About

John E. Janik, et al. 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma https://www.pnas.org/cgi/doi/10.1073/pnas.1516107112

NEWS CRUNCH  
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management - Technologies for biotech and pharmaceutical industries
August:
Regenerative technology - Meat of the future
September:
Doctor Robot - The digital healthcare revolution
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy